Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease
M Alexander, A. Katrina Loomis, Jolyon Fairburn-Beech, et al.
BMC Medicine (2018) Vol. 16, Iss. 1
Open Access | Times Cited: 225

Showing 1-25 of 225 citing articles:

Non-alcoholic fatty liver disease
Elizabeth E. Powell, Vincent Wai‐Sun Wong, Mary E. Rinella
The Lancet (2021) Vol. 397, Iss. 10290, pp. 2212-2224
Closed Access | Times Cited: 1778
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
Daniel Q. Huang, Hashem B. El‐Serag, Rohit Loomba
Nature Reviews Gastroenterology & Hepatology (2020) Vol. 18, Iss. 4, pp. 223-238
Open Access | Times Cited: 1309
Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease
Laurent Castéra, Mireen Friedrich‐Rust, Rohit Loomba
Gastroenterology (2019) Vol. 156, Iss. 5, pp. 1264-1281.e4
Open Access | Times Cited: 1158
Advancing the global public health agenda for NAFLD: a consensus statement
Jeffrey V. Lazarus, Henry E. Mark, Quentin M. Anstee, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 19, Iss. 1, pp. 60-78
Open Access | Times Cited: 516
Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States
Zobair M. Younossi, Maria Stepanova, Janus P. Ong, et al.
Clinical Gastroenterology and Hepatology (2020) Vol. 19, Iss. 3, pp. 580-589.e5
Open Access | Times Cited: 415
Changing epidemiology, global trends and implications for outcomes of NAFLD
Vincent Wai‐Sun Wong, Mattias Ekstedt, Grace Lai‐Hung Wong, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 3, pp. 842-852
Open Access | Times Cited: 271
What's in a name? Renaming ‘NAFLD’ to ‘MAFLD’
Yasser Fouad, Imam Waked, Steven Bollipo, et al.
Liver International (2020) Vol. 40, Iss. 6, pp. 1254-1261
Open Access | Times Cited: 268
Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts
M Alexander, A. Katrina Loomis, Johan van der Lei, et al.
BMC Medicine (2019) Vol. 17, Iss. 1
Open Access | Times Cited: 248
Dietary Fructose and the Metabolic Syndrome
Marja‐Riitta Taskinen, Chris J. Packard, Jan Borén
Nutrients (2019) Vol. 11, Iss. 9, pp. 1987-1987
Open Access | Times Cited: 237
MAFLD: How is it different from NAFLD?
Cameron Gofton, Yadhavan Upendran, Ming‐Hua Zheng, et al.
Clinical and Molecular Hepatology (2022) Vol. 29, Iss. Suppl, pp. S17-S31
Open Access | Times Cited: 223
Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults
M Alexander, A. Katrina Loomis, Johan van der Lei, et al.
BMJ (2019), pp. l5367-l5367
Open Access | Times Cited: 218
Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis
Darren Jun Hao Tan, Cheng Han Ng, Snow Yunni Lin, et al.
The Lancet Oncology (2022) Vol. 23, Iss. 4, pp. 521-530
Open Access | Times Cited: 214
Redefining fatty liver disease: an international patient perspective
Gamal Shiha, Marko Korenjak, Wayne Eskridge, et al.
˜The œLancet. Gastroenterology & hepatology (2020) Vol. 6, Iss. 1, pp. 73-79
Closed Access | Times Cited: 163
Administrative Coding in Electronic Health Care Record‐Based Research of NAFLD: An Expert Panel Consensus Statement
Hannes Hagström, Leon A. Adams, Alina M. Allen, et al.
Hepatology (2021) Vol. 74, Iss. 1, pp. 474-482
Open Access | Times Cited: 156
Nonalcoholic Fatty Liver Disease and Recent Guideline Updates
Yukio Ando, Janice H. Jou
Clinical Liver Disease (2021) Vol. 17, Iss. 1, pp. 23-28
Open Access | Times Cited: 147
Defining comprehensive models of care for NAFLD
Jeffrey V. Lazarus, Quentin M. Anstee, Hannes Hagström, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 10, pp. 717-729
Closed Access | Times Cited: 104
Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology
Daniel Q. Huang, Amit G. Singal, Fasiha Kanwal, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 12, pp. 797-809
Closed Access | Times Cited: 82
Associations of muscle mass and grip strength with severe NAFLD: A prospective study of 333,295 UK Biobank participants
Fanny Petermann‐Rocha, Stuart R. Gray, Ewan Forrest, et al.
Journal of Hepatology (2022) Vol. 76, Iss. 5, pp. 1021-1029
Open Access | Times Cited: 79
Liver disease is a significant risk factor for cardiovascular outcomes – A UK Biobank study
Adriana Roca‐Fernández, Rajarshi Banerjee, Helena Thomaides‐Brears, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 5, pp. 1085-1095
Open Access | Times Cited: 55
Association of GLP-1 Receptor Agonists and Hepatocellular Carcinoma Incidence and Hepatic Decompensation in Patients With Type 2 Diabetes
Lindsey Wang, Nathan A. Berger, David C. Kaelber, et al.
Gastroenterology (2024) Vol. 167, Iss. 4, pp. 689-703
Open Access | Times Cited: 32
Gut microbiota and metabolic biomarkers in metabolic dysfunction–associated steatotic liver disease
Qichen Long, Fengming Luo, Binghui Li, et al.
Hepatology Communications (2024) Vol. 8, Iss. 3
Open Access | Times Cited: 18
Modeling the Health and Economic Impact of Pharmacologic Therapies for MASLD in the United States
C. K. Wallace, Ivane Gamkrelidze, Chris Estes, et al.
Journal of Hepatology (2025)
Open Access | Times Cited: 2
"Evolving epidemiology of HCC in Spain"
Margarita Sala, Sonia Pascual, Montserrat Roca, et al.
JHEP Reports (2025), pp. 101336-101336
Open Access | Times Cited: 2
A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe
Jeffrey V. Lazarus, Mattias Ekstedt, Giulio Marchesini, et al.
Journal of Hepatology (2019) Vol. 72, Iss. 1, pp. 14-24
Open Access | Times Cited: 142
The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease
Nahúm Méndez‐Sánchez, Marco Arrese, Adrián Gadano, et al.
˜The œLancet. Gastroenterology & hepatology (2020) Vol. 6, Iss. 1, pp. 65-72
Closed Access | Times Cited: 134
Page 1 - Next Page

Scroll to top